| Trial Name | Description |
| MA.39 |
Dr. Francisco Perera "not yet open" TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer. |
| PET ABC |
Dr. Phillip Blanchette Impact of 18F-FDG PET-CT versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer. |
| MAC.19 |
Dr. Steven Latosinsky A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy |
| MAC.21 BR |
Dr. J. Raphael A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial |
| NSABP B51 BR |
Dr. S. Latosinsky A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically |
| DUCHESS |
Dr. Francisco Perera Evaluation of the Ductal Carcinoma in Situ Score for Decisions on Radiotherapy in Patients with Low/Intermediate Risk DCIS |
| MAC.20 |
Dr. Phillip Blanchette Randomized Phase III trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer. |
| TreatER+ight BR |
Dr. T. Vandenberg Treatment of Canadian Postmenopausal Women with ER+ Advanced Breast Cancer in the Real-World Setting with Hormone Therapy +/- Targeted Therapy |
| MRI B-mets BR |
Dr. F. Perera Magnetic Imaging of Brain Metastases in Breast Cancer Patients, a Pilot Study of the Value of the balanced steady state free precession imaging (bSSFP) sequence in Detecting Additional Brain Metastases |
| IND.237 |
Dr. Phillip Blanchette "not yet open" A Phase II Study of CFI-400945 in Patients with Advanced/Metastatic Breast Cancer. |
| NRG BR002 |
Dr. Brian Yaremko A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer. |
| REaCT-BTA |
Dr. Phillip Blanchette A pragmatic randomized, multicentre trail comparing 4-weekly versus 12-weekly administration of bone-targeted agents in patients with bone metastases from either castration-resistant prostate cancer or breast cancer - The REaCT-BTA Study. |
| IMpassion BR |
Dr. T. Vandenberg A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Paclitaxel Compared with Placebo with Paclitaxel for Patients with Previously Untreated Inoperable Locall |
This information is updated by the Clinical Research Unit
